VolitionRx Limited (NYSE:VNRX) CEO Cameron John Reynolds Purchases 181,818 Shares

VolitionRx Limited (NYSE:VNRX) CEO Cameron John Reynolds purchased 181,818 shares of the business’s stock in a transaction dated Wednesday, March 26th. The shares were bought at an average price of $0.55 per share, with a total value of $99,999.90. Following the purchase, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at approximately $1,264,572.10. The trade was a 8.59 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

VolitionRx Stock Performance

Shares of NYSE VNRX opened at $0.55 on Friday. The firm has a market capitalization of $50.97 million, a P/E ratio of -1.53 and a beta of 1.09. VolitionRx Limited has a one year low of $0.43 and a one year high of $1.02. The company’s fifty day moving average is $0.59 and its two-hundred day moving average is $0.64.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on VNRX shares. StockNews.com assumed coverage on shares of VolitionRx in a research note on Friday. They issued a “sell” rating on the stock. D. Boral Capital restated a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a research report on Thursday, March 20th.

Institutional Trading of VolitionRx

A number of institutional investors have recently added to or reduced their stakes in VNRX. Northern Trust Corp lifted its position in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares during the period. Two Sigma Securities LLC purchased a new position in VolitionRx in the 4th quarter valued at approximately $29,000. Millennium Management LLC acquired a new position in VolitionRx during the fourth quarter worth $36,000. Geode Capital Management LLC raised its holdings in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. boosted its position in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.